Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
11.79
+0.05 (0.46%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Dr. Reddy's Laboratories stock has a consensus rating of "Hold" and an average price target of $13.37. The average 1-year stock price forecast is 13.40% higher than the current stock price, while the lowest is $11.41 (-3.22%) and the highest is $15.62 (+32.49%).
Price Target: $13.37 (+13.40%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Jun 18, 2026.
Analyst Ratings
The average analyst rating for Dr. Reddy's Laboratories stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $16 | Buy | Reiterates | $16 | +35.26% | Jun 18, 2026 |
Unknown Analyst Citi No rating | Citi | Sell Maintains n/a | Sell | Maintains | n/a | n/a | Apr 23, 2026 |
Financial Forecast
Revenue This Year
351.11B
from 335.93B
Increased by 4.52%
Revenue Next Year
394.10B
from 351.11B
Increased by 12.24%
EPS This Year
45.03
from 55.39
Decreased by -18.70%
EPS Next Year
60.30
from 45.03
Increased by 33.91%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.